|
Fast Facts About Genzyme Corporation
Founded:
|
1981
|
2009 Revenues:
|
$4.5 billion
|
CEO:
|
Henri A. Termeer
President 1983, CEO 1985, Chairman 1988
|
2009 R&D Spending:
|
$804 million
|
Employees Worldwide:
|
More than 12,000
|
Headquarters:
|
Cambridge, MA
|
Exchange and Symbol:
|
Nasdaq, GENZ
|
Areas of Focus:
|
Personalized Genetic Health, Renal Disease, Endocrinology, Biosurgery, Hematologic Oncology, Transplant, Immune Diseases
|
|
|
|
Top Products, based on FY 2009 Revenue:
|
Product Name
|
Disease/Condition
|
Revenue 2009
|
Cerezyme® (imiglucerase for injection)
|
Gaucher disease
|
$793 million
|
Sevelamer (Renagel® and Renvela®)
|
renal disease
|
$707 million
|
Fabrazyme® (agalsidase beta)
|
Fabry disease
|
$431 million
|
Synvisc® (hylan G-F 20)
|
osteoarthritis of the knee
|
$329 million
|
|
|
Key Pipeline Products:
|
Product Name
|
Disease/Condition
|
alemtuzumab
|
multiple sclerosis
|
mipomersen
|
high-risk hypercholesterolemia
|
eliglustat tartrate
|
Gaucher disease
|
International Presence:
|
Genzyme has more than 85 locations in over 40 countries, including 17 manufacturing facilities; the company's products are available in nearly 100 countries.
|
Charitable Contributions, FY 2009:
|
Global product donations, $74 million; U.S. cash contributions, $14 million.
|
|
Home
